RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.53%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.25B
AUM Growth
+$307M
Cap. Flow
+$95.8M
Cap. Flow %
2.95%
Top 10 Hldgs %
41.75%
Holding
101
New
19
Increased
28
Reduced
23
Closed
18
Avg Time Held
1 year
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$68.6M
2
ALLK icon
Allakos
ALLK
+$59.9M
3
WMGI
Wright Medical Group Inc
WMGI
+$58.6M
4
FATE icon
Fate Therapeutics
FATE
+$43.8M
5
REPL icon
Replimune Group
REPL
+$38.4M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.7M
2
WCG
Wellcare Health Plans, Inc.
WCG
+$56.5M
3
LH icon
Labcorp
LH
+$51.8M
4
INSM icon
Insmed
INSM
+$48.1M
5
CNC icon
Centene
CNC
+$39.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.24%
2 Miscellaneous 1.57%
3 Financials 1.28%
4 Energy 0.69%
5 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
1
DELISTED
Array Biopharma Inc
ARRY
$242M 7.44%
15,906,680
-71,900
-0.4% -$1.1M
2013 Q2
21 quarters
ATRA icon
2
Atara Biotherapeutics
ATRA
$95M
$174M 5.37%
168,749
+3,684
+2% +$3.6M
2014 Q4
15 quarters
FATE icon
3
Fate Therapeutics
FATE
$226M
$169M 5.19%
10,359,666
+3,703,704
+56% +$43.8M
2015 Q2
13 quarters
RGNX icon
4
Regenxbio
RGNX
$450M
$125M 3.85%
1,656,065
+94,890
+6% +$6.84M
2017 Q1
6 quarters
XNCR icon
5
Xencor
XNCR
$1.76B
$118M 3.63%
3,030,143
-116,900
-4% -$4.77M
2016 Q4
7 quarters
IMGN icon
6
DELISTED
Immunogen Inc
IMGN
$117M 3.59%
12,309,035
-6,907
-0.1% -$66.4K
2017 Q1
6 quarters
WVE icon
7
Wave Life Sciences
WVE
$613M
$114M 3.5%
2,273,307
+28,800
+1% +$1.3M
2015 Q4
11 quarters
ALDR
8
DELISTED
Alder Biopharmaceuticals
ALDR
$108M 3.33%
6,505,766
– –
2016 Q3
8 quarters
FOLD icon
9
DELISTED
Amicus Therapeutics
FOLD
$102M 3.13%
8,402,617
-2,109,115
-20% -$29.5M
2013 Q2
21 quarters
BOLD icon
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$88.8M 2.73%
2,243,356
+14,700
+0.7% +$548K
2016 Q3
8 quarters
CI icon
11
Cigna
CI
$76.5B
$77.1M 2.37%
+370,200
New +$68.6M
2018 Q3
0 quarters
LIVN icon
12
LivaNova
LIVN
$4.17B
$74.3M 2.29%
599,288
-500
-0.1% -$59K
2017 Q2
5 quarters
ARGX icon
13
argenx
ARGX
$51.8B
$73.9M 2.27%
974,506
+301,206
+45% +$26.7M
2017 Q4
3 quarters
IFRX icon
14
InflaRx
IFRX
$220M
$69.5M 2.14%
2,024,900
-2,800
-0.1% -$90.3K
2017 Q4
3 quarters
ALLK icon
15
DELISTED
Allakos
ALLK
$65.7M 2.02%
+1,459,892
New +$59.9M
2018 Q3
0 quarters
ELV icon
16
Elevance Health
ELV
$92.4B
$64.1M 1.97%
234,000
+88,000
+60% +$22.8M
2018 Q2
1 quarter
WMGI
17
DELISTED
Wright Medical Group Inc
WMGI
$63.1M 1.94%
+2,173,700
New +$58.6M
2018 Q3
0 quarters
ANAB icon
18
AnaptysBio
ANAB
$1.39B
$62.9M 1.93%
630,250
+111,000
+21% +$9.21M
2017 Q4
3 quarters
QURE icon
19
uniQure
QURE
$1.43B
$59.7M 1.84%
1,639,900
+15,500
+1% +$577K
2018 Q2
1 quarter
DCPH icon
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$57.2M 1.76%
1,476,580
-500
-0% -$18.5K
2017 Q3
4 quarters
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$52.2M 1.61%
1,778,300
+19,700
+1% +$763K
2018 Q2
1 quarter
ICUI icon
22
ICU Medical
ICUI
$4.08B
$51.5M 1.58%
181,972
-2,200
-1% -$644K
2017 Q1
6 quarters
WCG
23
DELISTED
Wellcare Health Plans, Inc.
WCG
$50M 1.54%
155,909
-199,100
-56% -$56.5M
2017 Q4
3 quarters
TNDM icon
24
Tandem Diabetes Care
TNDM
$1.13B
$45.8M 1.41%
+1,069,670
New +$37.4M
2018 Q3
0 quarters
SRRK icon
25
Scholar Rock
SRRK
$4.81B
$45.7M 1.4%
1,773,107
+22,699
+1% +$417K
2018 Q2
1 quarter
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2018 Portfolio in Review

As of Q3 2018, Redmile Group held 101 positions worth $3.25B, up 10% from $2.94B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group's Q3 2018 filing shows 19 new, 28 increased, 23 reduced and 18 closed positions. Its largest new stake was Cigna: 370,200 shares worth $77.1M. The largest sale was Alexion Pharmaceuticals, an estimated $60.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q3 2018 buy was Cigna: 370,200 shares worth $77.1M.
  • Redmile Group added most to Fate Therapeutics in Q3 2018, an estimated $43.8M increase.
  • Redmile Group's biggest Q3 2018 reduction was Wellcare Health Plans, Inc., cutting an estimated $56.5M.
  • Redmile Group fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $60.7M.
  • Redmile Group's ten largest holdings make up 42% of its $3.25B portfolio in Q3 2018.
  • Redmile Group opened 19 new positions and closed 18 in Q3 2018.
  • Redmile Group's portfolio value rose 10% quarter-over-quarter to $3.25B.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.